Week of June 4, 2012: Catalent Expands Fill–Finish Capabilities; Siegfried Acquires Alliance Medical Products; and More
Catalent Expands Fill–Finish Capabilities; Siegfried Acquires Alliance Medical Products; and More.
Boehringer Ingelheim has established a new EUR 50-million+ ($62.2 million+) pilot-plant facility for the production of newly developed APIs in Biberach, Germany. The new technical center will have a useable area of approximately 2700-m2 (29062.56 ft2) and will host four manufacturing bays including four synthesis laboratories, which will handle the transfer of processes from laboratory to technical scale. The facility will have 15 chemical reactors with volumes of 100 to 300 liters, and is scheduled for completion in early 2014. Read More
Catalent Pharma Solutions has completed construction of its newly renovated 3300-ft2 aseptic fill–finish manufacturing facility at Research Triangle Park, North Carolina. The product-development group conducts preformulation, formulation development, process development, and manufacturing support in addition to offering analytical development and stability capabilities. The sterile clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial-filling line capable of producing Phase I and Phase II clinical-trial materials. These fill–finish facilities are designed to comply with global GMP requirements. Read More
Eli Lilly has officially opened the Lilly China Research and Development Center (LCRDC) in Shanghai. The goal of the LCRDC is to discover diabetes medicines with mechanisms of action that can be tailored specifically for the Chinese population to delay the progression of the disease. Read More
Siegfried has acquired Alliance Medical Products (AMP), a sterile manufacturer, for $58 million. The purchase price specifies a contingent earn-out consideration subject to AMP meeting defined profitability goals for the fiscal year ended Dec. 31, 2013. Read More
Industry Briefs:
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
